
The Week In Psychedelics
Last week saw some interesting developments from two of the largest publicly-traded companies in the psychedelics space: MindMed and Atai Life Sciences. MindMed announced that the FDA has allowed it to advance with a phase 2 trial on LSD, the first commercial trial on the compound in over forty years. Atai launched a new portfolio company meant to assist its drug development efforts.